| Tislelizumab studied in …STUDIED_INderived200 of 409show all (up to 200) |
|---|
| → studied in | NCT07845916Phase 2 · not yet recruiting Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07847905Phase 1/Phase 2 · not yet recruiting A Phase I/II Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05981703Phase 1 · recruiting A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07414836Phase 1 · recruiting A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07733180Phase 2 · recruiting A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC · 409 trials list this drug (218 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07842887Phase 1 · not yet recruiting Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05152147Phase 3 · active not recruiting A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers · 409 trials list this drug (218 active) | — | — | Gastric Neoplasm,Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07468071Phase 1/Phase 2 · recruiting Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07315750Phase 3 · recruiting A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. · 409 trials list this drug (218 active) | — | — | Gastric Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07565740Phase 1 · recruiting Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC · 409 trials list this drug (218 active) | — | — | Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04387084Phase 1 · active not recruiting Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy · 409 trials list this drug (218 active) | — | — | Malignant Skin Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04734262Phase 2 · active not recruiting A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) · 409 trials list this drug (218 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07829926Phase 2 · not yet recruiting Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer · 409 trials list this drug (218 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06529523Phase 2 · recruiting Tislelizumab in People With Colorectal Cancer · 409 trials list this drug (218 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06233942Phase 1 · recruiting Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06427941Phase 1/Phase 2 · recruiting A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors · 409 trials list this drug (218 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07822542Phase 3 · not yet recruiting A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06596473Phase 1 · recruiting A Study of BG-C477 in Participants With Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07746141Phase 1 · recruiting A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05877820Phase 2 · completed A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC · 409 trials list this drug (218 active) | — | — | Fumarate Hydratase-Deficient Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07812467Phase 2 · not yet recruiting Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | Oral Cavity Squamous Cell Carcinoma,Oropharyngeal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05343325Phase 2 · active not recruiting The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC · 409 trials list this drug (218 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07801352Phase 2 · active not recruiting CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer · 409 trials list this drug (218 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07802821Phase 3 · not yet recruiting A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer · 409 trials list this drug (218 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04276493Phase 1/Phase 2 · completed Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab · 409 trials list this drug (218 active) | — | — | Malignant Breast Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05909904Phase 2 · completed A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | Malignant Head and Neck Neoplasm,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04170283Phase 3 · active not recruiting A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07700667Phase 2 · recruiting SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07739186Phase 2/Phase 3 · not yet recruiting A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) · 409 trials list this drug (218 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07554521Phase 2 · recruiting A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States · 409 trials list this drug (218 active) | — | — | Esophageal Squamous Cell Carcinoma,Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07775040Phase 2 · not yet recruiting Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07776340Phase 2 · not yet recruiting Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05977673Phase 2 · recruiting Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy · 409 trials list this drug (218 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05758116Phase 2 · completed Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06416410Phase 3 · recruiting JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation · 409 trials list this drug (218 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06091943Phase 1 · completed Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07136077Phase 2 · active not recruiting A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy · 409 trials list this drug (218 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07432984Phase 2 · not yet recruiting Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06673693Phase 2 · active not recruiting Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07475026Phase 3 · recruiting A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · 409 trials list this drug (218 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07669415Phase 2 · recruiting A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06914687Phase 2 · active not recruiting Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma · 409 trials list this drug (218 active) | — | — | Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06745908Phase 3 · recruiting Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07502300Phase 3 · recruiting A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) · 409 trials list this drug (218 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07729592Phase 2 · not yet recruiting Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome · 409 trials list this drug (218 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05609370Phase 1/Phase 2 · active not recruiting A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer · 409 trials list this drug (218 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07715396Phase 3 · not yet recruiting Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05531123Phase 2 · active not recruiting Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer · 409 trials list this drug (218 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07554456Phase 2/Phase 3 · recruiting A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) · 409 trials list this drug (218 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07686926Phase 2 · not yet recruiting Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II · 409 trials list this drug (218 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07691515Phase 3 · not yet recruiting Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma · 409 trials list this drug (218 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03736889Phase 2 · recruiting Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07694765Phase 1/Phase 2 · not yet recruiting A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07601737Phase 2 · recruiting Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | Head and Neck Neoplasm,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06585488Phase 1 · terminated A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification · 409 trials list this drug (218 active) | — | — | Solid Neoplasm,Malignant Gastric Neoplasm,Esophageal Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07685704Phase 2 · not yet recruiting Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study · 409 trials list this drug (218 active) | — | — | Malignant Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma,HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07010120Phase 1/Phase 2 · active not recruiting A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07609121Phase 2 · recruiting Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07040956Phase 2 · completed A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients. · 409 trials list this drug (218 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07662811Phase 2/Phase 3 · not yet recruiting SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04649385Phase 1 · completed BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07671339Phase 1 · recruiting A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer · 409 trials list this drug (218 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07672223Phase 3 · not yet recruiting A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07385703Phase 3 · recruiting Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. · 409 trials list this drug (218 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07652736recruiting A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06884670Phase 2 · completed Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study · 409 trials list this drug (218 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07662395Phase 2/Phase 3 · recruiting SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03967977Phase 3 · active not recruiting Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma · 409 trials list this drug (218 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06541639Phase 1 · recruiting EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07502768Phase 1/Phase 2 · recruiting Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma · 409 trials list this drug (218 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07655661Phase 2 · not yet recruiting Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. · 409 trials list this drug (218 active) | — | — | Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07633873Phase 3 · not yet recruiting SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06167785Phase 2 · recruiting A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05789069Phase 1 · active not recruiting A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | Melanoma,Malignant Gastric Neoplasm,Lung Non-Small Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06422520Phase 1 · completed A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04164199Phase 3 · completed Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04539444Phase 2 · completed A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma · 409 trials list this drug (218 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06914011Phase 3 · not yet recruiting Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05542342Phase 2 · completed Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. · 409 trials list this drug (218 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05211232Phase 3 · active not recruiting Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma · 409 trials list this drug (218 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06010303Phase 2 · completed A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | Malignant Esophageal Neoplasm,Esophageal Squamous Cell Carcinoma,Esophageal Squamous Cell Carcinoma by AJCC v8 Stage | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05431270Phase 1/Phase 2 · recruiting Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07331155Phase 2 · recruiting A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07390383Phase 2 · recruiting A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04746924Phase 3 · terminated A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05661955Phase 1/Phase 2 · active not recruiting A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. · 409 trials list this drug (218 active) | — | — | Melanoma,Transitional Cell Carcinoma,Urothelial Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06487858Phase 1 · terminated A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07019675Phase 2 · recruiting A Study of SKB518 in Patients With Lung Cancer · 409 trials list this drug (218 active) | — | — | Lung Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06349837Phase 1 · recruiting Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07030140Phase 2 · recruiting Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma · 409 trials list this drug (218 active) | — | — | Malignant Bile Duct Neoplasm,Cholangiocarcinoma,Hilar Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07099547Phase 2 · recruiting Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma · 409 trials list this drug (218 active) | — | — | Biliary Tract Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07561060Phase 1/Phase 2 · recruiting Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy · 409 trials list this drug (218 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07561983Phase 2 · not yet recruiting Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07453875Phase 1 · not yet recruiting LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer · 409 trials list this drug (218 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05253118Phase 2 · active not recruiting Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS) · 409 trials list this drug (218 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06536868Phase 2 · recruiting Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC · 409 trials list this drug (218 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07353294Phase 1 · enrolling by invitation Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC · 409 trials list this drug (218 active) | — | — | Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05519865Phase 2 · completed A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06233981Phase 2 · completed Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis · 409 trials list this drug (218 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05635708Phase 2 · active not recruiting A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07531979Phase 2 · not yet recruiting Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07528274Phase 2 · recruiting Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03957590Phase 3 · completed A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07518706Phase 2 · not yet recruiting Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · 409 trials list this drug (218 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06848465Phase 1 · recruiting LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis · 409 trials list this drug (218 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03744468Phase 1/Phase 2 · completed Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05516914Phase 1/Phase 2 · completed A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors · 409 trials list this drug (218 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05807776Phase 2 · completed Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. · 409 trials list this drug (218 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05984602Phase 1 · active not recruiting A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer · 409 trials list this drug (218 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06868732Phase 1 · recruiting Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05982522Phase 1/Phase 2 · withdrawn IN10018 Combination Therapy in Previously-treated Solid Tumors · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563245Phase 2/Phase 3 · recruiting Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment · 409 trials list this drug (218 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04379635Phase 3 · active not recruiting Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04699188Phase 1/Phase 2 · active not recruiting Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation · 409 trials list this drug (218 active) | — | — | Neoplasm,Lung Neoplasm,Malignant Lung Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06540066Phase 1 · terminated A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors · 409 trials list this drug (218 active) | — | — | Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05935098Phase 1 · terminated BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07469306Phase 2 · not yet recruiting Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · 409 trials list this drug (218 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05526924Phase 1 · recruiting Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer · 409 trials list this drug (218 active) | — | — | Head and Neck Neoplasm,Malignant Head and Neck Neoplasm,Head and Neck Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04486391Phase 3 · terminated Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma · 409 trials list this drug (218 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07039162Phase 2 · recruiting Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | Malignant Esophageal Neoplasm,Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04282018Phase 1/Phase 2 · completed Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab · 409 trials list this drug (218 active) | — | — | Solid Neoplasm,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05116085Phase 2 · completed Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer · 409 trials list this drug (218 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05577702Phase 2 · completed Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07396090NA · not yet recruiting Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07388758Phase 2 · not yet recruiting Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma · 409 trials list this drug (218 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07389187early Phase 1 · not yet recruiting Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07383116Phase 3 · not yet recruiting Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer · 409 trials list this drug (218 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07373990Phase 3 · not yet recruiting Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma · 409 trials list this drug (218 active) | — | — | Malignant Nasopharyngeal Neoplasm,Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06764355Phase 2 · recruiting Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07370337Phase 2 · recruiting Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal · 409 trials list this drug (218 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05366829Phase 2 · recruiting Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma · 409 trials list this drug (218 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07346807Phase 2 · not yet recruiting Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer · 409 trials list this drug (218 active) | — | — | Tongue Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07348107Phase 1 · not yet recruiting ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma. · 409 trials list this drug (218 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07341360early Phase 1 · recruiting Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei · 409 trials list this drug (218 active) | — | — | Pseudomyxoma Peritonei | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05651022Phase 1/Phase 2 · active not recruiting Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | Adult Solid Neoplasm,Colorectal Carcinoma,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06312982Phase 2/Phase 3 · recruiting A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer · 409 trials list this drug (218 active) | — | — | Rectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07330037Phase 2 · recruiting TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07331428Phase 2 · not yet recruiting MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC · 409 trials list this drug (218 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07317609Phase 1 · recruiting Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02) · 409 trials list this drug (218 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06494189Phase 1 · completed Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma · 409 trials list this drug (218 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04294160Phase 1 · terminated A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06722183Phase 2 · recruiting Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities · 409 trials list this drug (218 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07296705Phase 2 · recruiting Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07059299Phase 1 · recruiting A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma · 409 trials list this drug (218 active) | — | — | Esophageal Adenocarcinoma,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06856837Phase 2 · recruiting - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases · 409 trials list this drug (218 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05886439Phase 1/Phase 2 · recruiting LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer · 409 trials list this drug (218 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05189457Phase 2 · active not recruiting First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer · 409 trials list this drug (218 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07264647Phase 2 · recruiting Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC) · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04974047Phase 2 · completed Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07157969Phase 2 · recruiting ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC · 409 trials list this drug (218 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05547321Phase 1 · recruiting Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07244705Phase 1/Phase 2 · recruiting A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC · 409 trials list this drug (218 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05238883Phase 1 · active not recruiting A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | Malignant Mesothelioma,Melanoma,Sarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06804850Phase 2 · withdrawn Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC · 409 trials list this drug (218 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07233252Phase 2 · recruiting Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05622071Phase 2 · completed Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions · 409 trials list this drug (218 active) | — | — | Hepatocellular Carcinoma by BCLC Stage | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03412773Phase 3 · completed A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) · 409 trials list this drug (218 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04363801Phase 2 · terminated A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer · 409 trials list this drug (218 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm,Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04215978Phase 1 · completed Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | Solid Neoplasm,Head and Neck Squamous Cell Carcinoma,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04318080Phase 2 · completed Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma · 409 trials list this drug (218 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06124378Phase 2 · active not recruiting Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer · 409 trials list this drug (218 active) | — | — | Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04047186Phase 2 · completed Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05014815Phase 2 · completed Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05904496Phase 1 · terminated A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05267054Phase 1/Phase 2 · completed Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab · 409 trials list this drug (218 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05014828Phase 2 · completed To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors · 409 trials list this drug (218 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05880082Phase 2 · completed PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer · 409 trials list this drug (218 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04047862Phase 1 · completed Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07132008Phase 3 · not yet recruiting Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer · 409 trials list this drug (218 active) | — | — | Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07126119Phase 2 · recruiting Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC · 409 trials list this drug (218 active) | — | — | Renal Pelvis and Ureter Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06333769Phase 2 · completed Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06323382recruiting Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma · 409 trials list this drug (218 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04570410Phase 2 · completed Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma · 409 trials list this drug (218 active) | — | — | Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07025850Phase 1/Phase 2 · not yet recruiting Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer · 409 trials list this drug (218 active) | — | — | Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05517330Phase 2 · completed Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03783442Phase 3 · completed A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07086456Phase 2 · recruiting Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06940388Phase 2 · recruiting Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer. · 409 trials list this drug (218 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05604560Phase 2 · active not recruiting A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer · 409 trials list this drug (218 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07077369Phase 1 · not yet recruiting WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy · 409 trials list this drug (218 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06793917Phase 3 · recruiting Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma · 409 trials list this drug (218 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07046221Phase 2 · not yet recruiting Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery · 409 trials list this drug (218 active) | — | — | Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07068516Phase 3 · not yet recruiting Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer · 409 trials list this drug (218 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04577963Phase 1/Phase 2 · terminated A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors · 409 trials list this drug (218 active) | — | — | Adult Solid Neoplasm,Malignant Colorectal Neoplasm,Triple-Negative Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06379087Phase 2 · recruiting Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07047586Phase 2 · recruiting Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab · 409 trials list this drug (218 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04921358Phase 3 · terminated Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04963088Phase 1/Phase 2 · completed Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT) · 409 trials list this drug (218 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07031700Phase 2 · not yet recruiting A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL · 409 trials list this drug (218 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05461794Phase 2 · terminated Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07019181Phase 2 · not yet recruiting Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma · 409 trials list this drug (218 active) | — | — | Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05319574Phase 2 · active not recruiting SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05771181Phase 2 · recruiting Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients · 409 trials list this drug (218 active) | — | — | Malignant Colorectal Neoplasm,Microsatellite Stable Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05044871Phase 2 · completed Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer · 409 trials list this drug (218 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06009861Phase 2 · active not recruiting Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) · 409 trials list this drug (218 active) | — | — | Oral Cavity Squamous Cell Carcinoma,Oropharyngeal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06446726Phase 2 · recruiting Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma · 409 trials list this drug (218 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06969612Phase 1 · recruiting A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06598527Phase 3 · recruiting Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study · 409 trials list this drug (218 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05516589Phase 2 · completed Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC · 409 trials list this drug (218 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06659042Phase 2 · recruiting Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer · 409 trials list this drug (218 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |